IASO Biotherapeutics, a clinical-stage biopharmaceutical developing and manufacturing cell therapies and antibody products, and Innovent Biologics, Inc. announced the FDA has granted Orphan Drug Designation (ODD) to their fully human anti-B-cell maturation antigen (BCMA) chimeric antigen receptor (CAR) T-cell therapy (IASO Bio: CT103A, Innovent: IBI326) for the treatment of relapsed and/or refractory multiple myeloma (R/R MM).   This ODD will accelerate drug development and registration action...